stockrowRepligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.
- Revenue
- +10.9%
- EPS
- −351.9%
- Free cash flow
- −11.5%
- Total debt
- +3.28%
Quarter to September 2026, against a year earlier
Follow RGEN
Alert me
Repligen Corporation (RGEN) Return on assets
Repligen Corporation's return on assets over the twelve months to 30 September 2026 was −0.40%, down 2.1 percentage points from fiscal 2025 (1.69%). Over the past ten years it has ranged from −0.90% (fiscal 2024) to 7.61% (fiscal 2022); the current reading is higher than 27% of that period. That is below the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 1.69% | 2.59 |
| FY2024 | −0.90% | (2.23) |
| FY2023 | 1.33% | (6.28) |
| FY2022 | 7.61% | 1.59 |
| FY2021 | 6.02% | 2.39 |
| FY2020 | 3.63% | 1.66 |
| FY2019 | 1.97% | (0.22) |
| FY2018 | 2.19% | (3.30) |
| FY2017 | 5.49% | 0.12 |
| FY2016 | 5.37% | (1.44) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ALGN Align Technology, Inc. compare | 7.71% |
| ATR AptarGroup, Inc. compare | 5.23% |
| COO The Cooper Companies, Inc. compare | 4.55% |
| AVTR Avantor, Inc. compare | 2.89% |
| SOLV Solventum Corporation compare | 1.11% |
| RGEN Repligen Corporation | −0.40% |
| BLCO Bausch + Lomb Corporation compare | −0.80% |
| BAX Baxter International Inc. compare | −3.57% |
| TFX Teleflex Incorporated compare | −14.6% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on RGEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement